Liftstream is an executive search recruitment company in the life sciences sector
Albumedix A/S announced on January 4th 2017 that it has appointed Dr. Giles Campion as Chief Medical Officer (CMO). Dr Campion brings with him more than 25 years’ experience in drug development from both large pharma and biotech companies having worked in senior development positions in the US as well as Europe.
PhaseBio Pharmaceuticals, a clinical-stage biopharmaceutical company head-quartered in Malvern, PA, has appointed John Lee as Chief Medical Officer based in Malvern and John Sharp as Chief Financial officer based in San Diego.
aTyr Pharma, a San Diego-based biotherapeutics company addressing rare diseases, has appointed Sanjay Shukla as Chief Medical Officer. Shukla will lead aTyr’s clinical efforts to advance its Physiocrine biology therapeutic intervention points and develop medicines that promote tissue homeostasis for patients with rare diseases.
Rigel Pharmaceuticals, a clinical-stage biotechnology company focused on immunology, oncology and immuno-oncology, has appointed Anne-Marie Duliege as chief medical officer to replace Elliott Grossbard, who is to retire after 14 years of service. Grossbard will remain with the company, advising on the new drug application (NDA) filing and regulatory strategy for fostamatinib in immune thrombocytopenic purpura (ITP).
Amplyx Pharmaceuticals, a San Diego-based company developing antifungal agents for the treatment of life-threatening fungal infections, has appointed Michael Hodges as chief medical officer, Karen Shaw as vice president of biology, and Elizabeth Gordon as vice president of regulatory affairs. The firm recently raised an USD8.7 million investment from 3×5 Partners, increasing its series B financing to USD49.2 million.
Ascendis Pharma, a clinical stage biotechnology company based in Copenhagen, and offices in Palo Alto, has appointed Jonathan A. Leff as Chief Medical Officer to replace Acting Chief Medical Officer Michael Beckert. Beckert will continue his consulting role with the company with a focus on leading the company’s European clinical operations.
Abide Therapeutics, a biotechnology company with research operations in San Diego and clinical development centre in Princeton, has appointed Chan Beals as Chief Medical Officer. In July 2015, Abide began enrolment in its first clinical study, a Phase 1a clinical study of ABX-1431, which is an investigational endocannabinoid system modulator with potential indications in symptomatic improvement in multiple sclerosis, neuroinflammation, acute and chronic pain, agitation in Alzheimer’s Disease and pain in irritable bowel syndrome. “With our first clinical study launched, the time is ideal to bring Beals aboard as we expand this program and advance our follow on first-in-class therapeutics,” commented Abide CEO Alan Ezekowitz.
Blueprint Medicines, a company discovering and developing highly selective investigational kinase medicines for patients with genomically defined diseases, has appointed Kathryn (Kate) Haviland as Chief Business Officer, who will be responsible for the firm’s corporate strategy, business development, corporate communications and investor relations functions.
Nimbus Therapeutics, a biotechnology company focused on harnessing the power of computational chemistry to design breakthroughs for serious, underserved diseases, today announced the appointment of Annie C. Chen, M.D., M.P.H., as Chief Medical Officer. Dr. Chen brings more than a decade of industry experience and joins Nimbus from Merck & Co., where she most recently served as Executive Director of Clinical Research, Section Head of Vaccines.
Selecta Biosciences raises $38m in Series E funding and also appoints Earl (‘Skip’) Sands, MD, as Chief Medical Officer (CMO). The company is a clinical stage biotech developing a novel class of targeted antigen-specific immune therapies. Proceeds from the financing will be used to advance multiple product candidates from Selecta’s Synthetic Vaccine Particle (SVP) platform, which creates antigen-specific immunotherapeutics, with priority implementation of the clinical program for Selecta’s lead immunotherapeutic candidate, SEL-212, which is designed to be the first nonimmunogenic biologic therapy for gout.